Duration and stability of metabolically healthy obesity over 30 years

被引:32
作者
Camhi, Sarah M. [1 ]
Must, Aviva [2 ]
Gona, Philimon N. [1 ]
Hankinson, Arlene [3 ]
Odegaard, Andrew [4 ]
Reis, Jared [5 ]
Gunderson, Erica P. [6 ]
Jacobs, David R. [7 ]
Carnethon, Mercedes R. [3 ]
机构
[1] Univ Massachusetts, Boston, MA 02125 USA
[2] Tufts Univ, Boston, MA 02111 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA
[6] Kaiser Permanente Northern Calif, Cardiovasc & Metab Condit Sect, Div Res, Oakland, CA USA
[7] Univ Minnesota, Minneapolis, MN USA
关键词
US POPULATION; UNITED-STATES; OVERWEIGHT; RISK; PREVALENCE; IDENTIFICATION; DISEASE; PROFILE; MATTER; ADULTS;
D O I
10.1038/s41366-018-0197-8
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background Obese adults who are free from metabolic risk factors may develop risk factors over time. Our objective was to characterize development of obesity and duration of metabolically healthy obese (MHO) over 30 years. Methods Participants in CARDIA who developed obesity (BMI >= 30 kg/m(2)) at follow-up exams during years 7, 10, 15, 20, 25, and 30 were analyzed. MHO was defined as obese and having 0 or 1 risk factor: >= SBP/DBP 130/85 mmHg; fasting glucose >= 100 mg/dL/5.55 mmol/L; fasting triglycerides (>= 150 mg/dL/1.69 mmol/L); and HDL-C (men < 40 mg/dL/1.036 mmol/L, women < 50 mg/dL/1.295 mmol/L) or on any medication(s) for these conditions. MHO duration (years) and obesity duration (years) were estimated for each subsequent time-point; and an overall cumulative duration was also calculated over available follow-up. MHO duration (%) was approximated as MHO duration divided by obesity duration. Stable MHO was defined as 100% MHO duration over follow-up, while transient MHO was defined as < 1-99%. Chi-squared tests were used to compare proportions by sex and race across obesity phenotypes. Multivariable-adjusted ANCOVA, adjusting for baseline BMI, age, race, and sex, was used to analyze obesity duration in all individuals who developed obesity, and also compare MHO duration (%) across race and sex in transient MHO individuals. Results Of the 987 eligible participants who developed obesity, 51% were African American (AA), 56% were women. Higher percentages of AA were classified as transient MHO, and higher proportions of females were MHO (both p < 0.0001). Obesity duration (years) was higher in transient MHO compared with stable MHO (mean difference: 6.2 +/- 0.5 years, p < 0.0001). Of those with transient MHO, African Americans (51.4 +/- 1.6%) were more likely to have longer MHO duration compared to Caucasians (44.4 +/- 1.9%, p = 0.005). Conclusion MHO status can be a transient phenotype which differs by sex and race. Future studies are needed to explore modifiable lifestyle/behavioral predictors associated with longer MHO duration.
引用
收藏
页码:1803 / 1810
页数:8
相关论文
共 35 条
[1]
Predicting the development of the metabolically healthy obese phenotype [J].
Achilike, I. ;
Hazuda, H. P. ;
Fowler, S. P. ;
Aung, K. ;
Lorenzo, C. .
INTERNATIONAL JOURNAL OF OBESITY, 2015, 39 (02) :228-234
[2]
Diabetes and Cardiovascular Disease Outcomes in the Metabolically Healthy Obese Phenotype [J].
Appleton, Sarah L. ;
Seaborn, Christopher J. ;
Visvanathan, Renuka ;
Hill, Catherine L. ;
Gill, Tiffany K. ;
Taylor, Anne W. ;
Adams, Robert J. .
DIABETES CARE, 2013, 36 (08) :2388-2394
[3]
The Natural Course of Healthy Obesity Over 20 Years [J].
Bell, Joshua A. ;
Hamer, Mark ;
Sabia, Severine ;
Singh-Manoux, Archana ;
Batty, G. David ;
Kivimaki, Mika .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (01) :101-102
[4]
What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? [J].
Brochu, M ;
Tchernof, A ;
Dionne, IJ ;
Sites, CK ;
Eltabbakh, GH ;
Sims, EAH ;
Poehlman, ET .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1020-1025
[5]
Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men [J].
Chang, Y. ;
Ryu, S. ;
Suh, B-S ;
Yun, K. E. ;
Kim, C-W ;
Cho, S-I .
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (09) :1187-1194
[6]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]
DISTRIBUTION OF LIPOPROTEINS AND APOLIPOPROTEINS IN YOUNG-ADULTS - THE CARDIA STUDY [J].
DONAHUE, RP ;
JACOBS, DR ;
SIDNEY, S ;
WAGENKNECHT, LE ;
ALBERS, JJ ;
HULLEY, SB .
ARTERIOSCLEROSIS, 1989, 9 (05) :656-664
[8]
Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855
[9]
Eckel N., 2018, Lancet Diabetes Endocrinol
[10]
Overweight and obesity in the United States: prevalence and trends, 1960-1994 [J].
Flegal, KM ;
Carroll, MD ;
Kuczmarski, RJ ;
Johnson, CL .
INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (01) :39-47